Anti-VEGF monotherapy safe and effective for SRNVM

Article

Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel).

Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel), claims a paper in the journal Retina.

The retrospective chart review led by Dr Raja Narayanan, L. V. Prasad Eye Institute, Hyderabad, India, included 16 eyes of 16 patients with naïve SRNVM secondary to Mactel examined between January 2007 and April 2011. Four eyes were administered intravitreal ranibizumab monotherapy and 12 were treated with intravitreal bevacizumab monotherapy.

The primary outcome was the mean change in best-corrected visual acuity (BCVA) at the final postoperative visit. Secondary outcomes included the mean number of intravitreal injections, retinal thickness on OCT and IOP. Demographic data, medical history and ocular history were also recorded.

Mean baseline visual acuity was 0.17 ± 0.16 and the mean final visual acuity was0.27 ± 0.14. No injection-related complications were reported and the mean amount of intravitreal injections was 1.9.

To read the abstract please click here.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.